OmniAb has unveiled its cutting-edge high-throughput single B-cell screening platform, xPloration®, at the 21st Annual PEGS Boston Summit, one of the premier global conferences for protein and antibody engineering. The xPloration® platform represents a significant advancement in antibody discovery, utilizing proprietary technology to isolate and analyze individual B cells with unprecedented speed and specificity. This allows for the rapid identification of therapeutic antibody candidates with desired characteristics, including high affinity and target specificity.
The xPloration® system streamlines the drug development process by enabling researchers to efficiently screen thousands of individual B cells in parallel, reducing the time required for lead candidate selection. With its ability to directly access immune repertoires from immunized animals, xPloration® also preserves native antibody diversity, which is crucial for developing more effective and safer biologic therapies. This platform is particularly valuable in accelerating the development of next-generation monoclonal antibodies and bispecifics for complex diseases such as cancer and autoimmune disorders.
OmniAb’s demonstration of xPloration® at PEGS Boston highlights its commitment to advancing biologic research tools and enabling faster innovation in therapeutic development. As pharmaceutical and biotech companies seek more efficient ways to generate high-quality antibodies, xPloration® positions OmniAb as a key technology provider in the biologics space. The platform’s potential to significantly shorten development timelines while maintaining scientific rigor marks a transformative step in the future of precision medicine.
MedTech Spectrum's Summary
OmniAb’s xPloration® platform enables ultra-high-throughput single B-cell antibody screening, accelerating the discovery of therapeutic candidates.
The technology enhances precision and efficiency, preserving antibody diversity while reducing lead identification time.
Its showcase at PEGS Boston signals OmniAb’s leadership in antibody discovery, supporting faster, targeted drug development in complex disease areas.
